Cannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications Review and Outlook

February 21, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is covering Cannabics Pharmaceuticals, Inc. (CNBX) today. Cannabics operates in the Marijuana industry that has rapidly and recently turned into a multi-billion dollar massive growth market across the US and Canada, with many new states legalizing it for either medical or recreational use. According to recent estimates, the cannabis market crossed $6.7 billion in the U.S. alone in 2016, and that the sale of cannabis products is set to rise to $22.8 billion in the U.S. by 2020.

Cannabics stock has unsurprisingly found enormous strength in the recent past. It has been surging due to the favorable impact of the company’s recent announcements and growing popularity of the industry.

A comprehensive analysis of Cannabics technology and fundamentals is available: READ MORE

(Copy and paste to browser may be required to view this report –

Cannabics Pharmaceuticals Inc. is a US based company founded in 2012 by Israeli researchers from the fields of molecular biology and cancer. CNBX’s entire R&D activity is based in Israel and involves both scientific and academic research, as well as current ongoing medical clinical studies which are registered with the US NIH.

CBD Products, Therapies, and Treatments continue to advance through research and development breakthroughs, prompting a strong forecast for 2017 performance.

The following Cannabics report includes a CBD industry over view and just how rare CNBX may be: READ MORE

(Copy and paste to browser may be required to view this report –


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated, directly or indirectly, for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst. For further information on analyst credentials, please email Vikas Agrawal, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information, which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments, reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email between 09:30 EST to 16:00 EST from Monday through Friday at:

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE: Traders News Source